Mesoblast Limited Dividend History (MESO)
Mesoblast Limited does not pay dividends currently 😔
They might in the future, check back soon!
About Mesoblast Limited
Mesoblast Limited is a biopharmaceutical company that specializes in developing innovative cellular medicines. Founded in 2004, the company is headquartered in Melbourne, Australia. Mesoblast focuses on treating severe and complex diseases by harnessing the power of its proprietary mesenchymal lineage adult stem cells. The company conducts extensive research and clinical trials to address diseases such as inflammatory ailments, cardiovascular conditions, and spine and orthopedic disorders. As of the latest available data, Silviu Itescu serves as the CEO and has been pivotal in advancing Mesoblast's mission to improve treatment outcomes through regenerative medicine. Mesoblast is listed on the Australian Securities Exchange (ASX: MSB) and the Nasdaq (MESO), offering insights into its robust R&D initiatives and market progress. Despite facing challenges typical to biotech companies, Mesoblast remains committed to innovation and the development of its promising therapeutic cell technologies.
Apple Inc.
Microsoft Corporation
Johnson & Johnson
Procter & Gamble Co.
Coca-Cola Co.
PepsiCo, Inc.
Exxon Mobil Corporation
Verizon Communications Inc.
AT&T Inc.
Chevron CorporationThe graft versus host disease market is experiencing significant growth, driven by the adoption of branded therapies, a strong pipeline with the anticipated launch of over 10 new drugs, and increased awareness of GvHD management. Innovative treatments and ongoing research are expected to further expand market opportunities.
GlobeNewswire Inc. · Published on Sun Sep 22 2024